Published in Ann Hematol on July 30, 2008
Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol (2012) 0.88
Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia. Pediatr Rheumatol Online J (2011) 0.86
A Case of Non-Hodgkin's Lymphoma in Patient with Coombs' Negative Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura. Cancer Res Treat (2012) 0.77
Evans syndrome with non-ST segment elevation myocardial infarction complicated by hemopericardium. Indian Heart J (2015) 0.75
Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations. Clin Rheumatol (2008) 0.75
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation (2012) 2.07
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol (2014) 1.59
Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One (2008) 1.45
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol (2007) 1.35
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica (2013) 1.32
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood (2010) 1.26
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol (2009) 1.21
Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant (2012) 1.20
Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem (2006) 1.19
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev (2006) 1.12
In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells. Blood (2006) 1.08
Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant (2011) 1.04
Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol (2009) 1.01
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer (2002) 1.01
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci (2009) 1.01
Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat. Cell Transplant (2009) 1.00
Interleukin 1 receptor antagonist polymorphisms are associated with the risk of developing acute coronary syndrome in Mexicans. Immunol Lett (2010) 1.00
Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction. Cell Transplant (2012) 0.98
CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids (2013) 0.98
Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer (2009) 0.96
Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) (2011) 0.96
Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica (2011) 0.95
Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion (2009) 0.94
Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Lett (2003) 0.94
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol (2007) 0.93
MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Hum Immunol (2007) 0.90
Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report. Cases J (2009) 0.90
P-glycoprotein in autoimmune diseases. Autoimmun Rev (2004) 0.90
Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine (2002) 0.90
Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int (2011) 0.89
Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. Microbes Infect (2004) 0.89
Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology (2009) 0.88
Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol (2012) 0.88
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol (2010) 0.88
[The bacillus Calmette-Guérin as immunomodulator in bladder cancer]. Rev Invest Clin (2007) 0.88
Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol (2004) 0.88
Adipose stromal vascular fraction improves cardiac function in chronic myocardial infarction through differentiation and paracrine activity. Cell Transplant (2012) 0.87
Cyclist's doping associated with cerebral sinus thrombosis. Neurology (2002) 0.87
Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) (2013) 0.87
The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica (2007) 0.87
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood (2013) 0.86
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res (2003) 0.86
Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest (2011) 0.86
Class I and class II MHC polymorphisms in Mexican patients with Behçet's disease. Immunol Lett (2004) 0.85
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol (2002) 0.85
Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica (2004) 0.85
IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis. J Clin Immunol (2012) 0.84
Inflammatory profile in the cerebrospinal fluid of patients with central neuropsychiatric lupus, with and without associated factors. Rheumatology (Oxford) (2009) 0.84
The role of indoleamine 2,3 dioxygenase in the induction of immune tolerance in organ transplantation. Transplant Rev (Orlando) (2010) 0.83
Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol (2010) 0.83
Prolonged idiotypic vaccination against follicular lymphoma. Leuk Lymphoma (2009) 0.83
TSPAN33 is a novel marker of activated and malignant B cells. Clin Immunol (2013) 0.82
Systemic lupus erythematosus in Hispanics. Autoimmunity (2011) 0.82
Peripheral regulatory cells immunophenotyping in kidney transplant recipients with different clinical profiles: a cross-sectional study. J Transplant (2012) 0.82
P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol (2008) 0.82
In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol (2012) 0.81
Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochem Biophys Res Commun (2007) 0.81
Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol (2004) 0.81
Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica (2003) 0.81
Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol (2012) 0.80
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leuk Res (2011) 0.80
Genetic variations in toll-like receptor 4 in Mexican-Mestizo patients with intra-abdominal infection and/or pneumonia. Immunol Lett (2013) 0.80
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther (2007) 0.80
Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials (2013) 0.79
Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res (2009) 0.79
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol (2014) 0.79
Peripheral regulatory cells immunophenotyping in primary Sjögren's syndrome: a cross-sectional study. Arthritis Res Ther (2013) 0.79
Common variable immunodeficiency and Evans syndrome complicated by autoimmune hemolysis due to anti-Jka auto-antibodies. Leuk Lymphoma (2008) 0.79
Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus. J Transl Med (2012) 0.78
Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica (2009) 0.78
Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genet Cytogenet (2003) 0.78
Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol (2004) 0.78
Polymerized-type I collagen induces upregulation of Foxp3-expressing CD4 regulatory T cells and downregulation of IL-17-producing CD4⁺ T cells (Th17) cells in collagen-induced arthritis. Clin Dev Immunol (2011) 0.78
Constitutive phosphorylation of interferon receptor A-associated signaling proteins in systemic lupus erythematosus. PLoS One (2012) 0.78
In vivo IL-10 and TGF-beta production by PBMC from long-term kidney transplant recipients with excellent graft function: a possible feedback mechanism participating in immunological stability. Clin Transplant (2004) 0.77
Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res (2006) 0.77
Utility of serum S100B protein for identification of central nervous system involvement in systemic lupus erythematosus. J Rheumatol (2010) 0.77
Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma (2004) 0.77
Lack of involvement of P-glycoprotein (P-gp) in pemphigus patients with poor response to steroid therapy. J Dermatol Sci (2002) 0.77
Human leukocyte antigen class I, class II, and tumor necrosis factor-alpha polymorphisms in a healthy elder Mexican Mestizo population. Immun Ageing (2005) 0.77
Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation. Eur J Haematol (2012) 0.77
The T29C polymorphism of the transforming growth factor-β1 (TGF-β1) gene is associated with genetic susceptibility to acute coronary syndrome in Mexican patients. Cytokine (2012) 0.76
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol (2011) 0.76
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol (2002) 0.76
EF/SSc overlap syndrome and aplastic anaemia resistant to immunosuppressive therapy. Rheumatology (Oxford) (2012) 0.76
Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases. Rheumatology (Oxford) (2011) 0.76
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms? Immunology (2014) 0.76
Absence of salivary CCL28 in primary Sjögren's syndrome. Rheumatol Int (2015) 0.76